Summary
24.32 0.20(0.81%)09/27/2024
Genmab (GMAB)
Genmab (GMAB)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.81 | -4.82 | -12.83 | -4.93 | -20.57 | -31.60 | 22.99 | 544.62 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 24.32 | |
| Open | 24.27 | |
| High | 24.43 | |
| Low | 24.23 | |
| Volume | 449,330 | |
| Change | 0.20 | |
| Change % | 0.81 | |
| Avg Volume (20 Days) | 476,940 | |
| Volume/Avg Volume (20 Days) Ratio | 0.94 | |
| 52 Week Range | 23.81 - 36.12 | |
| Price vs 52 Week High | -32.68% | |
| Price vs 52 Week Low | 2.12% | |
| Range | 0.19 | |
| Gap Up/Down | 0.15 | |
Fundamentals | ||
| Market Capitalization (Mln) | 15,318 | |
| EBIDTA | 3,416,250,112 | |
| PE Ratio | 54.3403 | |
| PEG Ratio | 5.6579 | |
| WallStreet Target Price | 46.36 | |
| Book Value | 32.5510 | |
| Earnings Per Share | 0.6601 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 4.5500 | |
| EPS Estimate Next Year | 7.6100 | |
| Diluted EPS (TTM) | 0.6601 | |
| Revenues | ||
| Profit Marging | 0.3634 | |
| Operating Marging (TTM) | 0.3943 | |
| Return on asset (TTM) | 0.0857 | |
| Return on equity (TTM) | 0.1445 | |
| Revenue TTM | 7,906,999,808 | |
| Revenue per share TTM | 12.0909 | |
| Quarterly Revenue Growth (YOY) | 0.3400 | |
| Quarterly Earnings Growth (YOY) | 0.6750 | |
| Gross Profit (TTM) | 10,111,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 54.3403 | |
| Forward PE | 51.2821 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.6621 | |
| Revenue Enterprise Value | 2.8119 | |
| EBITDA Enterprise Value | 6.2089 | |
| Shares | ||
| Shares Outstanding | 654,036,992 | |
| Shares Float | 1,293,577,251 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 7.18 | |
09/26 15:17 EST - globenewswire.com
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
09/15 08:45 EST - globenewswire.com
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Media Release COPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed across FRα expression levels Phase 3 trial will further evaluate the safety and efficacy of Rina-S at 120 mg/m 2 in patients with advanced ovarian cancer Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate (ADC), demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W), regardless of FRα expression levels. These data were from the dose expansion part of a multi-part study evaluating the safety and efficacy of single-agent Rina-S in ovarian cancer (OC) and endometrial cancer (EC).
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Media Release COPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed across FRα expression levels Phase 3 trial will further evaluate the safety and efficacy of Rina-S at 120 mg/m 2 in patients with advanced ovarian cancer Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate (ADC), demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W), regardless of FRα expression levels. These data were from the dose expansion part of a multi-part study evaluating the safety and efficacy of single-agent Rina-S in ovarian cancer (OC) and endometrial cancer (EC).
09/10 16:06 EST - globenewswire.com
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
08/26 12:26 EST - globenewswire.com
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 2 2 nd Annual Global Healthcare Conference at 1 : 05 P M E D T / 7 : 05 P M CEST on September 4 , 202 4.
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 2 2 nd Annual Global Healthcare Conference at 1 : 05 P M E D T / 7 : 05 P M CEST on September 4 , 202 4.
08/23 11:55 EST - seekingalpha.com
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year.
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year.
08/19 14:00 EST - globenewswire.com
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy COPENHAGEN, Denmark; August 19, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU), as well as the European Economic Area (EEA) countries (Iceland, Liechtenstein, Norway) and Northern Ireland.
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy COPENHAGEN, Denmark; August 19, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU), as well as the European Economic Area (EEA) countries (Iceland, Liechtenstein, Norway) and Northern Ireland.
08/16 09:00 EST - globenewswire.com
Genmab Announces Changes to its Executive Committee
Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology Officer Brad Bailey appointed as Executive Vice President and Chief Commercial Officer Anthony Mancini, Executive Vice President and Chief Operating Officer, will leave Genmab to pursue other opportunities Genmab A/S (Nasdaq: GMAB ) today announced changes to its Executive Committee to support Genmab's growth and evolution into a fully integrated biotech innovation powerhouse. Genmab's Executive Committee will include Rayne Waller in the newly created role of Executive Vice President and Chief Technology Officer and Brad Bailey in the newly created role of Executive Vice President and Chief Commercial Officer.
Genmab Announces Changes to its Executive Committee
Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology Officer Brad Bailey appointed as Executive Vice President and Chief Commercial Officer Anthony Mancini, Executive Vice President and Chief Operating Officer, will leave Genmab to pursue other opportunities Genmab A/S (Nasdaq: GMAB ) today announced changes to its Executive Committee to support Genmab's growth and evolution into a fully integrated biotech innovation powerhouse. Genmab's Executive Committee will include Rayne Waller in the newly created role of Executive Vice President and Chief Technology Officer and Brad Bailey in the newly created role of Executive Vice President and Chief Commercial Officer.
08/13 14:53 EST - globenewswire.com
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
08/08 11:03 EST - globenewswire.com
Genmab Announces Financial Results for the First Half of 2024
August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate technology platforms The U.S. Food and Drug Administration (U.S. FDA) approved EPKINLY ® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of conditional marketing authorization of TEPKINLY ® (epcoritamab) for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy Tivdak ® (tisotumab vedotin-tftv) received full U.S. FDA approval to treat recurrent or metastatic cervical cancer Genmab submitted a Japan New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) in Japan for Tivdak (tisotumab vedotin) for the treatment of adult patients with advanced or recurrent cervical cancer that has progressed on or after chemotherapy Genmab revenue increased 36% compared to the first six months of 2023, to DKK 9,545 million Genmab 2024 financial guidance updated “In the second quarter of 2024, we reached a number of significant milestones for the company. The acquisition of ProfoundBio, along with the regulatory approvals for EPKINLY and Tivdak, further solidify our commitment to the development of differentiated antibody therapies and will advance Genmab towards our ambitious 2030 vision of transforming the lives of patients with our innovative antibody medicines,” said Jan van de Winkel, Ph.D.
Genmab Announces Financial Results for the First Half of 2024
August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate technology platforms The U.S. Food and Drug Administration (U.S. FDA) approved EPKINLY ® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of conditional marketing authorization of TEPKINLY ® (epcoritamab) for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy Tivdak ® (tisotumab vedotin-tftv) received full U.S. FDA approval to treat recurrent or metastatic cervical cancer Genmab submitted a Japan New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) in Japan for Tivdak (tisotumab vedotin) for the treatment of adult patients with advanced or recurrent cervical cancer that has progressed on or after chemotherapy Genmab revenue increased 36% compared to the first six months of 2023, to DKK 9,545 million Genmab 2024 financial guidance updated “In the second quarter of 2024, we reached a number of significant milestones for the company. The acquisition of ProfoundBio, along with the regulatory approvals for EPKINLY and Tivdak, further solidify our commitment to the development of differentiated antibody therapies and will advance Genmab towards our ambitious 2030 vision of transforming the lives of patients with our innovative antibody medicines,” said Jan van de Winkel, Ph.D.
08/08 11:00 EST - globenewswire.com
Genmab Updates 2024 Financial Guidance
Company Announcement Genmab updates its 2024 financial guidance Increase in revenue driven by higher royalties and reimbursement revenue Increase in operating profit excluding acquisition and integration charges, driven by higher revenue and focused investments COPENHAGEN, Denmark; August 8, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it is updating its 2024 financial guidance last published on May 2, 2024, following the acquisition of ProfoundBio, Inc. (ProfoundBio). The revised guidance reflects an updated revenue outlook, incremental R&D investment to support the advancement of ProfoundBio's clinical programs, primarily rinatabart sesutecan (Rina-S), as well as acquisition and integration related charges.
Genmab Updates 2024 Financial Guidance
Company Announcement Genmab updates its 2024 financial guidance Increase in revenue driven by higher royalties and reimbursement revenue Increase in operating profit excluding acquisition and integration charges, driven by higher revenue and focused investments COPENHAGEN, Denmark; August 8, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it is updating its 2024 financial guidance last published on May 2, 2024, following the acquisition of ProfoundBio, Inc. (ProfoundBio). The revised guidance reflects an updated revenue outlook, incremental R&D investment to support the advancement of ProfoundBio's clinical programs, primarily rinatabart sesutecan (Rina-S), as well as acquisition and integration related charges.
08/05 05:50 EST - globenewswire.com
Genmab Takes Full Control of Acasunlimab Development Program
Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development of the acasunlimab program under the parties' existing collaboration agreement The overall collaboration between the companies to continue unchanged COPENHAGEN, Denmark; August 5, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it will assume sole responsibility for the continued development and potential commercialization of acasunlimab. BioNTech SE (BioNTech) has opted not to participate in the further development of the acasunlimab program under the parties' existing collaboration agreement.
Genmab Takes Full Control of Acasunlimab Development Program
Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development of the acasunlimab program under the parties' existing collaboration agreement The overall collaboration between the companies to continue unchanged COPENHAGEN, Denmark; August 5, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it will assume sole responsibility for the continued development and potential commercialization of acasunlimab. BioNTech SE (BioNTech) has opted not to participate in the further development of the acasunlimab program under the parties' existing collaboration agreement.
08/02 10:56 EST - zacks.com
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet
The consensus price target hints at a 45.1% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet
The consensus price target hints at a 45.1% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
08/02 08:22 EST - zacks.com
Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.
Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.
07/29 13:00 EST - zacks.com
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
07/25 12:41 EST - zacks.com
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
07/17 10:56 EST - zacks.com
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade
The consensus price target hints at a 52.3% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade
The consensus price target hints at a 52.3% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
07/17 06:25 EST - globenewswire.com
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
Company Announcement Net sales of DARZALEX ® in the second quarter of 2024 totaled USD 2,878 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 17, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson & Johnson were USD 2,878 million in the second quarter of 2024. Net trade sales were USD 1,641 million in the U.S. and USD 1,237 million in the rest of the world.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
Company Announcement Net sales of DARZALEX ® in the second quarter of 2024 totaled USD 2,878 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 17, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by Johnson & Johnson were USD 2,878 million in the second quarter of 2024. Net trade sales were USD 1,641 million in the U.S. and USD 1,237 million in the rest of the world.
07/09 12:45 EST - zacks.com
GMAB or TECH: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
GMAB or TECH: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Genmab A/S Sponsored ADR (GMAB) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?